Fu-Shan Xue | Clinical Medicine | Outstanding Scientist Award

Posted on by Pencis

Prof. Fu-Shan Xue | Clinical Medicine | Outstanding Scientist Award

Fuzhou University Affiliated Provincial Hospital | China

Author Profile

Scopus

Orcid ID

🎓 THE REMARKABLE JOURNEY OF FU-SHAN XUE: A TRAILBLAZER IN ANESTHESIOLOGY

🎓 EARLY ACADEMIC PURSUITS

Fu-Shan Xue’s academic journey laid a strong foundation for his outstanding future career. His deep passion for medical sciences, particularly anesthesiology and surgery, led him to pursue rigorous academic training, culminating in his appointment as a Doctoral Supervisor. His dedication during his formative academic years built the groundwork for his later roles as a Chief Physician and Distinguished Professor at Beijing Anzhen Hospital, Capital Medical University.

🏥 PROFESSIONAL ENDEAVORS

Dr. Xue’s professional career is marked by exceptional achievements and prestigious appointments. Serving as the Chief Physician and Professor at the Anesthesiology and Surgery Center of Beijing Anzhen Hospital, he became one of the leading figures in the field. Beyond his hospital responsibilities, he has been recognized as:

  • National Candidate of the "New Century Millions of Talents Project",

  • Expert with Special Allowance of the State Council,

  • Young and Middle-Aged Expert with Outstanding National Contributions,

  • Leading Talent of the National "Ten-Thousand Talents Program".

These distinctions reflect his national and international stature as a pioneering anesthesiologist.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON CLINICAL MEDICINE

Dr. Xue has significantly advanced the field of anesthesiology through his extensive research and innovation. His focus spans various critical areas, including:

  • Innovative techniques in anesthesia and perioperative medicine,

  • Enhancing patient safety during surgical procedures,

  • Developing new surgical and anesthetic methodologies.

His contributions have led to real-world advancements in clinical practices, making surgeries safer and improving patient outcomes.

🌍 IMPACT AND INFLUENCE

The impact of Dr. Xue’s work extends far beyond the walls of his institution:

  • Published more than 1,180 academic papers, including over 830 as the first and corresponding author in SCI-indexed journals,

  • Edited and translated 15 professional books that serve as key references in the field,

  • Achieved 86 national patents (including 11 invention patents) and 10 foreign patents,

  • Honored with 8 prestigious awards at the provincial and ministerial levels.

Dr. Xue’s influence resonates through medical education, research innovation, and clinical excellence in China and globally.

📈 ACADEMIC CITATIONS

Given his prolific research output, Dr. Xue’s work has been widely cited across national and international medical communities. His extensive citation record demonstrates the foundational importance of his research in advancing anesthesiology and surgery disciplines. He stands as a major reference point for upcoming anesthesiologists and researchers worldwide.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Fu-Shan Xue’s legacy is already deeply entrenched in the history of anesthesiology:

  • A pioneer in bridging clinical practice and innovative research,

  • A mentor to new generations of physicians and researchers,

  • An architect of safer and more effective anesthesia practices.

Looking ahead, Dr. Xue continues to drive cutting-edge innovations, pursue international collaborations, and mentor young talents. His future contributions are expected to further revolutionize perioperative medicine, enhance global surgical standards, and inspire countless young professionals to follow in his footsteps.

🏅 AWARDS AND HONORS

  • China Distinguished Research Award of Anaesthesia

  • China Distinguishable Anaesthetist Award

  • Wu Yang Medical Medicine Award

  • Nie Jiedong Medical Award

  • Health Defender of Healthy China

  • Top 10 Innovative Medical Experts

These accolades underscore his unparalleled contributions to the advancement of medical science and patient care.

📑NOTABLE PUBLICATIONS

"The UCP2/PINK1/LC3b-mediated mitophagy is involved in the protection of NRG1 against myocardial ischemia/reperfusion injury" 

  • Authors: X., Li, Xintao , X., Li, Xinyue , T., Tian, Tian , M., Jin, Mu , F., Xue, Fushan
  • Journal: Redox Biology
  • Year: 2025

"Esketamine at a Clinical Dose Attenuates Cerebral Ischemia/Reperfusion Injury by Inhibiting AKT Signaling Pathway to Facilitate Microglia M2 Polarization and Autophagy" 

  • Authors: Y., Gao, Ying , L., Li, Lu , F., Zhao, Fang , M., Jin, Mu , F., Xue, Fushan
  • Journal: Drug Design, Development and Therapy
  • Year: 2025

"Subglottic airway injury during fiberscope-monitored intubation with a supraglottic airway device: A randomized controlled comparison of three tracheal tubes" 

  • Authors: K., Su, Kai , S., Xu, Shangjun , H., Wang, Haixia , F., Xue, Fushan , M., Tian
  • Journal: Ming Chinese Medical Journal
  • Year: 2025

Kang Yang | Metabolic Disorders | Best Researcher Award

Posted on by Pencis

Dr. Kang Yang | Metabolic Disorders | Best Researcher Award

Northern Jiangsu People's Hospital affiliated with Yangzhou University | China

Author Profile

Scopus

Orcid Id

EARLY ACADEMIC PURSUITS 🎓

Kang Yang embarked on his academic journey at Shandong First Medical University, where he pursued a Bachelor of Medicine (BM) in 2017 under the mentorship of Professor Jianhong Qi. His early interest in sports medicine and rehabilitation laid a strong foundation for his future contributions in the field.

Building on this, he further honed his expertise at Yangzhou University, obtaining a Master of Medicine (MM) in 2020 under the guidance of Professor Xianghe Chen. His postgraduate studies deepened his understanding of rehabilitation techniques, patient care, and innovative treatments in sports medicine.

PROFESSIONAL ENDEAVORS 💼

As a rehabilitation physician and therapist, Kang Yang is committed to enhancing the quality of life for patients recovering from injuries, surgeries, and physical impairments. His work integrates advanced rehabilitation methodologies with patient-centered approaches to ensure effective recovery and functional restoration.

Throughout his career, he has actively contributed to both clinical practice and academic research, focusing on rehabilitation strategies tailored for athletes and individuals with musculoskeletal disorders.

CONTRIBUTIONS AND RESEARCH FOCUS ON METABOLIC DISORDERS🔬

Kang Yang’s research primarily revolves around sports medicine and rehabilitation medicine. His investigations explore:

  • Innovative rehabilitation techniques for sports-related injuries.
  • Physiological and biomechanical adaptations in long-distance runners and athletes.
  • Post-injury recovery protocols aimed at optimizing healing and preventing re-injury.

His dedication to research has led to significant advancements in sports rehabilitation, with a particular focus on marathon runners and endurance athletes.

IMPACT AND INFLUENCE 🔍

Kang Yang's contributions extend beyond clinical settings. His work has influenced:

  • Rehabilitation strategies for sports professionals.
  • Medical education, through his involvement in teaching and mentoring young medical students.
  • Public awareness on the importance of injury prevention and rehabilitation in sports.

His clinical expertise and research have helped shape modern rehabilitation protocols, making a positive impact on both patient outcomes and medical practices.

ACADEMIC CITATIONS AND RECOGNITION 🏆

Kang Yang’s academic excellence has been recognized through multiple prestigious awards:

  • Special Prize (2018) & First Prize (2019) at the Jiangsu Sports Graduate Innovation Forum.
  • 2019 National Scholarship for Postgraduates (China).
  • First-class academic scholarship from Yangzhou University.

These accolades highlight his commitment to academic excellence, research innovation, and contributions to the medical community.

LEGACY AND FUTURE CONTRIBUTIONS🏰

Looking ahead, Kang Yang aims to:

  • Expand his research on sports rehabilitation and injury prevention.
  • Develop advanced therapeutic protocols for athletes and individuals recovering from physical trauma.
  • Collaborate with international experts to enhance rehabilitation medicine globally.
  • Continue mentoring students and young professionals in the field of rehabilitation sciences.

His unwavering passion and dedication position him as a future leader in the evolving landscape of sports medicine and rehabilitation.

BEYOND MEDICINE: PERSONAL INTERESTS 📚

Outside of his professional life, Kang Yang enjoys:

  • Long-distance running and marathons, reflecting his deep understanding of sports medicine from both a theoretical and practical perspective.
  • Reading, staying updated with the latest medical advancements and broadening his intellectual horizons.

NOTABLE PUBLICATIONS📑

"Exercise alleviates renal interstitial fibrosis by ameliorating the Sirt1-mediated TGF-β1/Smad3 pathway in T2DM mice" 

  • Authors: X., Chen, Xianghe , X., Zeng, Xinyu , X., Qiu, Xiao , X., Zhou, Xiangxiang , K., Yang, Kang
  • Journal: Endocrine Connections
  • Year: 2024

Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Posted on by Pencis

Dr. Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Gregorio Maranon University Hospital | Spain

Author Profile

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Since 2017, I have been dedicated to advancing the field of pharmacogenetics, beginning as a research assistant and progressing through to postdoctoral researcher at the Pharmacogenetics Laboratory of the Gregorio Marañón General University Hospital. My journey started with foundational research roles and evolved into leadership positions within various pharmacogenomic studies.

PROFESSIONAL ENDEAVORS

Starting as a research assistant, I gradually transitioned to roles as a predoctoral and postdoctoral researcher, accumulating invaluable experience and expertise in pharmacogenetics. My work has been primarily focused on pharmacogenomic studies in diverse medical areas such as colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases.

CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACOGENMICS AND PERSONALIZED MEDICINE

Throughout my career, I have actively contributed to 21 publications in pharmacogenomics, with a particular emphasis on colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases. Of these publications, I served as the first author for 14, showcasing my significant contributions to the field. Notably, my doctoral thesis in 2020 centered on intestinal inflammatory disease, underscoring my commitment to advancing knowledge in this area.

IMPACT AND INFLUENCE

My contributions have not gone unnoticed, as evidenced by receiving the AEFA (Spanish Clinical Laboratory Association) award for quality and innovation in 2019. Additionally, my research has been recognized through presentations at 20 national and international conferences, including 5 oral communications. I have been honored with the best oral communication award at three conferences, highlighting the impact of my work.

ACADEMIC CITES

My research has contributed to the academic discourse, with citations in various publications, further validating the significance and influence of my work in pharmacogenetics awards and related fields.

LEGACY AND FUTURE CONTRIBUTIONS

As an active member of the Spanish Society of Pharmacogenetics awards and the Spanish Association of Human Genetics, I continue to contribute to the advancement and dissemination of knowledge in these critical areas of public health. My ongoing commitment to research and collaboration ensures that my contributions will continue to shape the future of pharmacogenetics.

NOTABLE PUBLICATIONS

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children 2023(3)

Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease 2023(7)

Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort 2023(7)

Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain 2022(5)

Pharmacogenetics to avoid adverse reactions in cardiology: Ready for implementation? 2021(4)